The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD-Reference-Cited by-同舟云学术

The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD

Published:2022-07-03 Issue:9 Volume:39 Page:3881-3895
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Kolb Martin^ORCID,Orfanos Stylianos E.^ORCID,Lambers Chris^ORCID,Flaherty Kevin^ORCID,Masters Alison^ORCID,Lancaster Lisa^ORCID,Silverstein Adam^ORCID,Nathan Steven D.^ORCID

Funder

United Therapeutics Corporation

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02229-8.pdf

Reference57 articles.

1. Travis WD, Costabel U, Hansell DM, et al. An Official American Thoracic Society/European Respiratory Society Statement: update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.

2. Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25):D109–16.

3. Wollin L, Distler JHW, Redente EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019;54(3):1900161.

4. Ghumman M, Dhamecha D, Gonsalves A, et al. Emerging drug delivery strategies for idiopathic pulmonary fibrosis treatment. Eur J Pharm Biopharm. 2021;164:1–12.

5. Lambers C, Kornauth C, Oberndorfer F, et al. Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells. PLoS One. 2018;13(11): e0205195.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Therapies in Outpatient Pulmonary Medicine;Medical Clinics of North America;2024-09

2. Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus;Respiratory Medicine;2024-09

3. Highlights on Future Treatments of IPF: Clues and Pitfalls;International Journal of Molecular Sciences;2024-08-01

4. Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease;Inflammation and Regeneration;2024-07-19

5. Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date;Drug, Healthcare and Patient Safety;2024-06